Note: Descriptions are shown in the official language in which they were submitted.
'163~
4-14123/CGC 1002/DIS 2
OPUT~IALMIC PREPARATION
Glaucoma, manifesting itself by the turbidity and opacity of ocular
cornea, endangers especially persons of age over 50 and can even-
tually lead a total blindness. Observations indicate that there is a
relation between glaucoma and the intraocular pressure (IOP~ 9 and
that a pathologically increased IOP, also known as ocular hyper-
tension, is the principal condition for developing glaucoma. In the
past, attempts have been made to eliminate, or at least to retard,
the progress of the disease by lowering IOP either by surgery or by
drug medication.
It is known that in patients treated for various reasons by adrenergic
drugs, i.e. drugs exerting a physiological activity toward adreno-
receptors, a lowering of IOP is frequently encountered as a side
effect. This decrease in IOP was observed not only with orally
administered adrenoreceptor antagonists (especially those blocking
~-receptors such as propranolol and practolol), but also, for not
fully understood reasons, with adrenoreceptors agonists, especially
~-adrenergic stimulators such as terbutaline [2-tert-butyl-1-(3,5-
dihydroxyphenyl)-ethanol, disclosed in U.S. 4,011,258~ which is a
potent vaso- and bronchodilator, cf. K. Wettrell et al.: Experimental
Eye Research (1977) 24, 613-619 and the references cited therein.
In order to utilize this general effect in ophthalmologic thera-
peutic praxis, especially in control of excessive lOP (i.e. the
ocular hypertension) and glaucoma, the primary overall adrenergic
effect of an orally administered drug had to be minimized, whereas
the desirable "side-effect" onto the eye, i.e. the lowering of IOP,
.. ~
3'7
-- 2 --
should be retained if not potentiated. Fortunately, animal experiments
early indicated that these drugs exert their beneficial effect also
by topical administration. On this basis, epinephrine has been widely
used anti-glaucoma agent. However, a pervasive side effect of
epinephrine therapy is mydriasis, which is unfortunately largely un-
dissociable from the drug's ocular hypotensive action. More recently,
epinephrine dfpivalic ester, dipivefrin, has undergone extensive
development specifically intended for use in ocular hypertension and
glaucoma. The substance is about 10 times more potent (i.e. it brings
a comparable effect in a 10 times smaller dose) than the parent com-
pound, but is not more efficient than epinephrine in lowering IOP
(i.e. the maximum available decreasein(IOP irrespectively of doses
is the same in both substances). The smaller dose of the ester
necessary to lower IOP obviates some of the undesirable extraocular
side effects encountered with the relatively high therapeutic doses
necessary with epinephrine. The mydriasis, however, as well as other
intraocular side effects accompanying epinephrine, are unfortunately
likewise present with use of the dipivalate.
A more promising approach was expected by the topical application
of the ~-adrenoreceptor stimulators, whose ocular hypertensive
effect by oral route has been discussed above. In spite of some con-
troversial results [e.g. a potent ~-adrenergic stimulator prenalterol
was found ineffective in lowering IOP in normotensive human eye by
oral administration, c.f. A. Alm et al.: Acta Ophthalmologica 59,
882-887 (1981)], it has been generally established that by either
oral or topical adminstration, the decreases in IOP were significantly
more pronounced with drugs having strong ~2-adrenoreceptor stimulating
activity, such as isoproterenol, metaproterenol, salbutamol and
terbutaline, cf. D.E. Potter and J.M. Rowland: Experimental Eye
Research (1978) 27, 615-625. The association of lowering IOP with the
adrenergic activity, and especially with the ~2-receptor-stimulating,
vascular activity has been demonstrated also by suppressing experimental
~ ~ .
,
. - . . .
1~1ti3'~
ocular hypertension in rabbits, cf. J.M. Rowland and D.E. Potter:
Experimental Eye Research (1980) 30, 93-104. An analogous correlation
was also found for both normotensive and hypertensive human eye.
In addition to terbutaline, said U.S. 4,011,258 also disclosed
corresponding 3',5'-diesters of the parent compound with C2-C5 fatty
acids, especially the 3',5'-diisobutyrate, ibuterol, for use as
bronchodilators. However, the esters as such have only negligible
~2-stimulating activity and develop their effect only after having
been hydrolyzed in situ by endogenous esterases to form the ~2-
adrenoreceptor-stimulating parent substance terbutaline, see O.A.T.
Olsson et al.: Acta Pharmacologica et Toxicologica 35, 76 (1974).
Hence, the esters, including ibuterol, are bronchodilators of an
approximately equal potency as the parent drug, and ibuterol failed
to offer the expected advantage over terbutaline when applied as
bronchodilator by inhalation in asthmatic patients, see N. Mcl.
Johnson and S.W.Clarke: British Medical Journal 1977, 1006.
In the present invention, the unexpected finding has been made now
that ibuterol [1-(3,5-diisobutyryloxyphenyl)-2-tert-butyl)-ethanol],
as compared to the parent terbutaline as standard, reveals sur-
prisingly high effects in lowering IOP by topical application onto
a mammal's eye. The experimental data, summarized in Table I,
clearly establish that ibuterol not only possesses an increased
potency but also an improved efficacy as compared to terbutaline.
Whereas this reaches its greatest efficacy in decreasing lOP by
approximately 7% at a dose of lOO~u of a 2% solution, lOP reductions
amounting more than 10% can be achieved with the same amount (100 ~l)
of a much more diluted (0.05-0.1%) solution of ibuterol.
`,
: . . ' . ' ~ .
'
37
Table 1:
Mean Decrease in lOP l Hour After Topical Instil.*
dl-Terbutaline Ibuterol Sulfate
***** **
IOP-reduction IOP-reduction
conc. % mm Hg + SE r mm Hg + SE
4 6.9 + 0.8 0.1 9.8 + 0.8
2 7.1 + 0.8 0.05 10.4 + 0.6
0.2 3.8 + 0.7 0.01 6.2 + 0.9
0.06 3.3 + 0.9 0.005 7.7 + 1.0
; ~ 0.02 1 4.7 + L.4 1 ~ OOl I 4.2 ~ 1.3
* 6 rabbits in each experimental group;
** solution in distilled water, concentration calculated as
w/v-percentage of free base;
*** applied doses lOO~ul; SE = standard error
Based on these unexpected and surprising results, the present in-
vention relates in the first instance to an ophthalmic preparation
i for topical application to eye of a mammal containing an effective
; amount of 2-tert-butylamino-~3,5-diisobutyryloxyphenyl)-ethanol, or
a physiologically acceptable salt thereof, and a carrier~ and in
the second instance to a method for lowering IOP by the topical appli-
cation onto the eye of a mammal, inclusive, in particular, the human
eye, of a physiologically active amount of ibuterol, preferably in
admixture with a therapeutically acceptable carrier. By the topical
application, the drug can be brought onto freely accessible surface
parts of the eyeball in a manner conventional in ophthalmology, e.g.
by applying it in a semi-solid form (such as paste, cream, lotion
: ;:.
''~ ' '''
. ;' ' . ' , . ~ :. '' . ~
.' ~ . '~ , ' :
:, : ..
. - - ., - - .
3'~
or gel) or, in particular, in a liquid form (such as eye bath or,
especially~ eye drops), or also, in a solid form as an ophthalmic
insert for a slow drug release. A physiologically effective amount
of the drug is such as being capable, on application onto the eye
surface of the subject, to bring about an estimable and effective
decrease in IOP.
The active principle, i.e. ibuterol, is a compound known per se,
which can be used in form of its racemate (+-ibuterol) as of an
individual optical isomer thereof. All these forms are applicable
both as the free base and as a therapeutically, especially ophthal-
mically, tolerable acid addition salt. (Owing to the close relation-
ship of ibuterol as the free base and its salts, hereinbefore and
hereinafter, the terms "ibuterol" shall, unless specially
distinguished, also include the salts thereof, especially pharma-
ceutically acceptable salts thereof, and the term "salts" shall also
include the free base, wherever appropriate.)
Suitable acid addition salts of ibuterol are, in particular, physio-
logically tolerable salts, preferably those with conventional in-
organic and organic acids which are generally known to be capable
of producing therapeutically, and in particular, ophthalmically
tolerable acid addition salts. Of the inorganic acids, mention
should be made of hydrohalic acids (such as hydrobromic and, pre-
ferably, hydrochloric acid) as well as oxygen-containing acids (such
as, especially, sulfuric, phosphoric and boric acid); of the organic
acids, mention should be made especially of sulfonic acids, e.g.
carbocyclic, especially aromatic, sulfonic acids (such as (+)-camphor-
10-sulfonic, p-toluenesulfonic, p-bromobenzenesulfonic, and benzene-
sulfonic acid) and alkanesulfonic acids, e.g. Cl-C7-lower alkane-
sulfonic acids (such as, especially, methanesulfonic acid) and also
of carboxylic acid, e.g. monobasic alkanoic acids (such as acetic,
propionic and lactic acid), polybasic aliphatic acids (such as
oxalic, malic, tartaric and citric acid) as well as carbocyclic
carboxylic acids (such as benzoic, p-chlorobenzoic, phenylacetic,
,
.. , . . - , : -
"'' ''' , ' ' . '.' ''' :' ' '
.
' '. ' ~' ' ~ , " . "' ' ~.
.' ' ' :
3'7
phenoxyacetic and phthalic acid).
Advantageously, ibuterol is applied to the eyeball in the form of
a pharmaceutical preparation conventionally formulated for this
purpose. Such a topical ophthalmic preparation comprising a physiolo-
gically effective amount of ibuterol or a therapeutically (especially
ophthalmically) tolerable acid addition salt thereof together with
at least one indifferent carrier, also belongs to the particular
embodiments of the invention.
In pharmaceutical preparations for the direct application to the eye-
ball (such as those mentioned hereinabove), the concentration of
ibuterol (calculated as the free base) generally amounts about 0.01
to about 1.0 weight-% (based on the weight of the final composition);
a preferred concentration, e.g. in eye drops, is about 0.025 to
about 0.5, especially 0.05 to 0.2 % (w/v).
In one embodiment, water is the principal inert carrier, deionized
and/or distilled water being used preferably. Advantageously, an
aqueous solution of the drug and other ingredients may be used
as a stock solution in the manufacture of other, non-homogeneous
application forms.
In order to prevent the aqueous solutions from the presence of germs
of noxious microorganisms, e.g. of those deteriorating or modifying
the components and, especially, of pathogenic microorganisms, the
primary solutions are preferably sterilized by conventional means
(e.g. ultra-filtration and/or heat treatment) and/or rendered
preserved, especially by the admixture of preservatives. Common
preservatives are applied in usual concentrations (in % w/v)~ e.g.
benzalkonium halides (especially chloride) in an amount of about
0.002 to about 0.02, especially about 0.01%, disodium EDTA, in an
amount of about 0.005 to about 0.05, especially about 0.025%, and/or
- .
.
3~
thimerosol in an a~ount of about 0.0002 to about 0.005, especially
about 0.001%. For the chemical stability, the presence of a conven-
tional antioxidant, such as sodium metabisulfite, in an appropriate
concentration (such as 0.025 to about 0.25%) is useful and recommend-
able.
For the ophthalmic tolerability, the pH of the solution should be
rendered within the limits of about 5 to about 8, preferably 6.0 to
7.5; advantageously, a constant pH is adjusted by means of a buffer.
Therapeutically tolerable and physiologically indifferent buffer com-
ponents, such as alkali metal acetates, bicarbonates, carbonates and,
especially, primary and secondary phosphates, as well as citric acid,
are to be used in relatively low concentrations, ordinarily not
exceeding 0.05~, in order to render the solution isotonic, or even
more diluted, with respect to tear fluid.
All the above-indicated concentration of the drug and the other
ingredients relate to formulations for a direct application to
the eyeball, such as,eSpecially~ eye drops. In preparations, which
are intended for a later dilution, e.g. as a stock solution for an
eye bath or as intermediate premixes for preparing other application
forms (e.g. semi-solid preparations), the components are mixed in
analogous relative proportions, but in an appropriately higher
overall concentration.
For a higher ocular comfort in the direct application as eye drops,
the solution may be thickened to a viscosity of about 5 to about
20, preferably about 10-15 cps, by adding a conventional thickening
agent, such as methylcellulose, hydroxypropylmethylcellulose or poly-
vinyl alcohol in an appropriate amount.
Also for the ocular comfort, the eye drops can be isotonic with tear
fluid; to this effect, an appropriate amount of sodium chloride,
3'7
- 8 ~
or an analogous neutral salt, especially a halide, can be added,
or advantageously, the concentration of the buffer component is
adjusted such as to meet this condition.
In general, adminstering of such aqueous solutions of the active
component is preferred which have been kept only for a known, limited
period of time, e.g. several days or one or two weeks, or, most
preferably, have been prepared immediately before the application.
To this effect, two-component pharmaceutical preparations are
especially useful, i.e. such as consisting of a solid component, pre-
ferably one in dosage unit form, which contains the active sub-
stance and some of the other solid ingredients, and of a separate
solvent component. The actual therapeutic co~position is obtained
on dissolving the solid component in the solvent component before
application, and can be applied in the usual manner in one single
treatment or kept for a limited time to be applied in a repeated
treatment. The solid-component preparation is preferably formulated
into a dosage unit form, especially into tablets, and can contain,
beside the active substance, also an antioxidant, buffering compounds,
such as those referred to, and/or agents adjusting osmotic pressure
and/or viscosity. The solvent component preparation can be water in
an appropriate state of purity or an aqueous solution containing e.g.
a preservative such as any of those mentioned above, and/or any of
the adjuvatory ingredients mentioned above, especially those which
are liquid or semi-solid or, for any other reason, incompatible with
the solid-component preparation, e.g. as being hygroscopic.
Advantageously, the relative proportions of the individual ingredients
in both the solid and the solvent component are chosen so that a
final solution is obtained which in its composition and concentration
corresponds to the preferred embodiments specified for the single-
component, aqueous preparations; also, an appropriate mutual pro-
portion of the solid and the solvent component may be chosen to the
same effect. The dosage units of the solid-component preparation
. ,
,
1 '21~;37
are preferably proportioned so that they provide, dissolved in
an appropriate quantity of the solvent component, a quantity of
an instantly applicable solution which is sufficient for at least
one single administration or, preferably, a multiple administration,
e.g. during one day.
Other pharmaceutical preparations applicable for the use in the
present invention, such as semi-solid application forms as mentioned
above, are also formulated according to methods conventional in
pharmaceutical arts and employing conventional ingredients. For
continuous release, the active component can also be incorporated
or enclosed in a semi-permeable plastic material which is conven-
tionally used for ophthalmologic purposes (such as for ocular inserts,
shells and lenses). The incorporation can be effected e g. by
building the drug into a molecular network of a polymer or by im-
pregnating a microporous material with a solution. In the latter
instance, e.g. a plastic lens can be kept in an isotonic solution
of ibuterol between its regular uses.
The dosage of the active component in a single application is, to
a large extent, independent of the body weight or the species of the
treated subject, and amounts, for the eye drops of the above-defined
composition and concentration range, about 0.03 to O.15, especially
about O.l ml to one eyeball. The treatment can be repeated, if
necessary, several times, e.g. up to a maximum of ô applications,
in a day. Equivalent dosage is applicable to the other dosage forms.
The invention also relates to the manufacture of the above-defined
topical ophthalmic pharmaceutical preparations. The manufacture
is effected by conventional non-chemical methods of the art by
blending, dissolving or mixing the active component with the other
ingredients and, if desired confectioning the primary product into
therapeutically applicable final forms.
' ~ '
, ' ,
.
3~
-- 10 --
The following Example, is set forth for purposes of illustration
but is in no way intended to limit the scope of the invention
thereto.
Example
Eye drops containing 0.1% (w/v) ibuterol (calculated as base)
are obtained as follows:
One liter of a buffer solution of pH 6.0 (which is 0.00374-molar
with respect to citric acid and 0.01252-molar with respect to di-
sodium phosphate) is prepared by mixing 374 ml of a O.Ol-molar stock
solution of citric acid and 626 ml of a 0.02-molar stock solution of
disodium phosphate. In this solution, the following ingredients are
dissolved at room temperature in the order as specified (dissolving
may be speeded up by stirring provided the contact with atmospheric
oxygen is rendered at a minimum):
1.0 g disodium metabisulfite
1.134 g isobuterol sulfate tequivalent to 1.0 g of the
free base)
0.1 g benzalkonium chloride
0.25 g disodium EDTA
5.0 g hydroxypropylmethylcellulose
This solution is sterilized by filtratiGn to obtain approximately
one liter of eye drops of a pH 6.0, which corresponds to 10000
regular single doses.
In a similar manner, other virtually neutral acid addition
salts of ibuterol can be used in quantities corresponding to the
amount of the free base. Also, ibuterol base can be used analogously
provided that it is neutralized by a molar equivalent of an acid,
e.g. citric acid.
. '' ,'' ', ' .
.
'
- , - :
;37
It is also possible to add the preservatives (benzalkonium chloride
and disodium EDTA) in corresponding quantities to the buffer stock
solutions, especially to the citric acid solution, in order to keep
them in the preserved condition.
